Radiolabeled iododeoxyuridine: Safety evaluation

Katherine A. Harrison, Glenn V. Dalrymple, Janina Baranowska-Kortylewicz, Karen P. Holdeman, Martin H. Schneiderman, Robert P. Lieberman, John G Sharp, Samuel Monroe Cohen, Peter K. Leichner, Samuel C. Augustine, Margaret A. Tempero, Rodney J. Taylor, Rei K. Chiou

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The emphasis of radiolabeled iododeoxyuridine (*IUdR) research at our institution to date has been to assess its safety as a potential therapeutic agent. Toward this goal, we have performed preclinical and clinical studies, using various routes of administration, to detect adverse changes in normal tissues in both humans and animals. As IUdR is rapidly dehalogenated by the liver, the intravenous route is unlikely to be successful in therapeutic efforts. We have therefore focused our attention on more "protected" routes: intra-arterial and intravesicular administration. Methods: Studies were performed in farm pigs after multiple administrations of [125I]IUdR into the aorta, carotid artery and bladder. IUdR and metabolites were measured in venous blood samples at appropriate time intervals after administration, after which histologic examination of tissues was performed. Studies in human have been performed after intra-arterial administration of [123I]IUdR in patients with liver metastases and intravesicular administration in patients with bladder carcinoma, initially using [123I]IUdR and currently using both [123I]IUdR and [125I]IUdR. Blood samples for pharmacokinetics and metabolite analysis and tissue for autoradiography (when feasible) have been obtained. Results: To date, no evidence of adverse effects on normal tissue or alteration of hematologic or metabolic indices have been seen in pigs or humans. When instilled in the bladder, there is little leakage of IUdR in the circulation. Conclusion: When [125I]IUdR is used as a therapeutic agent, we anticipate little or no effect on normal tissues.

Original languageEnglish (US)
Pages (from-to)13S-16S
JournalJournal of Nuclear Medicine
Volume37
Issue number4 SUPPL.
StatePublished - Apr 1 1996

Fingerprint

Idoxuridine
Safety
Urinary Bladder
Swine
Liver
Autoradiography
Carotid Arteries
Aorta
Therapeutics
Pharmacokinetics

Keywords

  • Auger electron emitters
  • Iodine-123
  • Iodine-125
  • Iododeoxyuridine

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Harrison, K. A., Dalrymple, G. V., Baranowska-Kortylewicz, J., Holdeman, K. P., Schneiderman, M. H., Lieberman, R. P., ... Chiou, R. K. (1996). Radiolabeled iododeoxyuridine: Safety evaluation. Journal of Nuclear Medicine, 37(4 SUPPL.), 13S-16S.

Radiolabeled iododeoxyuridine : Safety evaluation. / Harrison, Katherine A.; Dalrymple, Glenn V.; Baranowska-Kortylewicz, Janina; Holdeman, Karen P.; Schneiderman, Martin H.; Lieberman, Robert P.; Sharp, John G; Cohen, Samuel Monroe; Leichner, Peter K.; Augustine, Samuel C.; Tempero, Margaret A.; Taylor, Rodney J.; Chiou, Rei K.

In: Journal of Nuclear Medicine, Vol. 37, No. 4 SUPPL., 01.04.1996, p. 13S-16S.

Research output: Contribution to journalReview article

Harrison, KA, Dalrymple, GV, Baranowska-Kortylewicz, J, Holdeman, KP, Schneiderman, MH, Lieberman, RP, Sharp, JG, Cohen, SM, Leichner, PK, Augustine, SC, Tempero, MA, Taylor, RJ & Chiou, RK 1996, 'Radiolabeled iododeoxyuridine: Safety evaluation', Journal of Nuclear Medicine, vol. 37, no. 4 SUPPL., pp. 13S-16S.
Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP et al. Radiolabeled iododeoxyuridine: Safety evaluation. Journal of Nuclear Medicine. 1996 Apr 1;37(4 SUPPL.):13S-16S.
Harrison, Katherine A. ; Dalrymple, Glenn V. ; Baranowska-Kortylewicz, Janina ; Holdeman, Karen P. ; Schneiderman, Martin H. ; Lieberman, Robert P. ; Sharp, John G ; Cohen, Samuel Monroe ; Leichner, Peter K. ; Augustine, Samuel C. ; Tempero, Margaret A. ; Taylor, Rodney J. ; Chiou, Rei K. / Radiolabeled iododeoxyuridine : Safety evaluation. In: Journal of Nuclear Medicine. 1996 ; Vol. 37, No. 4 SUPPL. pp. 13S-16S.
@article{054e01e1425d41139ed29d16fb8d7f2b,
title = "Radiolabeled iododeoxyuridine: Safety evaluation",
abstract = "The emphasis of radiolabeled iododeoxyuridine (*IUdR) research at our institution to date has been to assess its safety as a potential therapeutic agent. Toward this goal, we have performed preclinical and clinical studies, using various routes of administration, to detect adverse changes in normal tissues in both humans and animals. As IUdR is rapidly dehalogenated by the liver, the intravenous route is unlikely to be successful in therapeutic efforts. We have therefore focused our attention on more {"}protected{"} routes: intra-arterial and intravesicular administration. Methods: Studies were performed in farm pigs after multiple administrations of [125I]IUdR into the aorta, carotid artery and bladder. IUdR and metabolites were measured in venous blood samples at appropriate time intervals after administration, after which histologic examination of tissues was performed. Studies in human have been performed after intra-arterial administration of [123I]IUdR in patients with liver metastases and intravesicular administration in patients with bladder carcinoma, initially using [123I]IUdR and currently using both [123I]IUdR and [125I]IUdR. Blood samples for pharmacokinetics and metabolite analysis and tissue for autoradiography (when feasible) have been obtained. Results: To date, no evidence of adverse effects on normal tissue or alteration of hematologic or metabolic indices have been seen in pigs or humans. When instilled in the bladder, there is little leakage of IUdR in the circulation. Conclusion: When [125I]IUdR is used as a therapeutic agent, we anticipate little or no effect on normal tissues.",
keywords = "Auger electron emitters, Iodine-123, Iodine-125, Iododeoxyuridine",
author = "Harrison, {Katherine A.} and Dalrymple, {Glenn V.} and Janina Baranowska-Kortylewicz and Holdeman, {Karen P.} and Schneiderman, {Martin H.} and Lieberman, {Robert P.} and Sharp, {John G} and Cohen, {Samuel Monroe} and Leichner, {Peter K.} and Augustine, {Samuel C.} and Tempero, {Margaret A.} and Taylor, {Rodney J.} and Chiou, {Rei K.}",
year = "1996",
month = "4",
day = "1",
language = "English (US)",
volume = "37",
pages = "13S--16S",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Radiolabeled iododeoxyuridine

T2 - Safety evaluation

AU - Harrison, Katherine A.

AU - Dalrymple, Glenn V.

AU - Baranowska-Kortylewicz, Janina

AU - Holdeman, Karen P.

AU - Schneiderman, Martin H.

AU - Lieberman, Robert P.

AU - Sharp, John G

AU - Cohen, Samuel Monroe

AU - Leichner, Peter K.

AU - Augustine, Samuel C.

AU - Tempero, Margaret A.

AU - Taylor, Rodney J.

AU - Chiou, Rei K.

PY - 1996/4/1

Y1 - 1996/4/1

N2 - The emphasis of radiolabeled iododeoxyuridine (*IUdR) research at our institution to date has been to assess its safety as a potential therapeutic agent. Toward this goal, we have performed preclinical and clinical studies, using various routes of administration, to detect adverse changes in normal tissues in both humans and animals. As IUdR is rapidly dehalogenated by the liver, the intravenous route is unlikely to be successful in therapeutic efforts. We have therefore focused our attention on more "protected" routes: intra-arterial and intravesicular administration. Methods: Studies were performed in farm pigs after multiple administrations of [125I]IUdR into the aorta, carotid artery and bladder. IUdR and metabolites were measured in venous blood samples at appropriate time intervals after administration, after which histologic examination of tissues was performed. Studies in human have been performed after intra-arterial administration of [123I]IUdR in patients with liver metastases and intravesicular administration in patients with bladder carcinoma, initially using [123I]IUdR and currently using both [123I]IUdR and [125I]IUdR. Blood samples for pharmacokinetics and metabolite analysis and tissue for autoradiography (when feasible) have been obtained. Results: To date, no evidence of adverse effects on normal tissue or alteration of hematologic or metabolic indices have been seen in pigs or humans. When instilled in the bladder, there is little leakage of IUdR in the circulation. Conclusion: When [125I]IUdR is used as a therapeutic agent, we anticipate little or no effect on normal tissues.

AB - The emphasis of radiolabeled iododeoxyuridine (*IUdR) research at our institution to date has been to assess its safety as a potential therapeutic agent. Toward this goal, we have performed preclinical and clinical studies, using various routes of administration, to detect adverse changes in normal tissues in both humans and animals. As IUdR is rapidly dehalogenated by the liver, the intravenous route is unlikely to be successful in therapeutic efforts. We have therefore focused our attention on more "protected" routes: intra-arterial and intravesicular administration. Methods: Studies were performed in farm pigs after multiple administrations of [125I]IUdR into the aorta, carotid artery and bladder. IUdR and metabolites were measured in venous blood samples at appropriate time intervals after administration, after which histologic examination of tissues was performed. Studies in human have been performed after intra-arterial administration of [123I]IUdR in patients with liver metastases and intravesicular administration in patients with bladder carcinoma, initially using [123I]IUdR and currently using both [123I]IUdR and [125I]IUdR. Blood samples for pharmacokinetics and metabolite analysis and tissue for autoradiography (when feasible) have been obtained. Results: To date, no evidence of adverse effects on normal tissue or alteration of hematologic or metabolic indices have been seen in pigs or humans. When instilled in the bladder, there is little leakage of IUdR in the circulation. Conclusion: When [125I]IUdR is used as a therapeutic agent, we anticipate little or no effect on normal tissues.

KW - Auger electron emitters

KW - Iodine-123

KW - Iodine-125

KW - Iododeoxyuridine

UR - http://www.scopus.com/inward/record.url?scp=0030118386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030118386&partnerID=8YFLogxK

M3 - Review article

C2 - 8676196

AN - SCOPUS:0030118386

VL - 37

SP - 13S-16S

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4 SUPPL.

ER -